eliapixant
oral P2X3 ion channel antagonist Ph. II, multiple settings (50-750 mg BID) from literature P2X3 antagonists Scientific Reports Bayer AG, Berlin, DE
Molecules of the Month - October 2021
Molecules of the Month
- BMS986278
- compound 4c
- AS-0141
- aficamten
- CP-628006
- reldesemtiv
- JNJ-A07
- eliapixant
- repotrectinib
- compound 10
- venglustat
- maralixibat
- compound 44
- compound 1